Condensed Consolidating Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating activities
Net income	$ 43,982	$ 23,463
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	1,364	4,911
Depreciation and amortization	46,771	42,539
Provision for bad debts	85	781
Equity in earnings of unconsolidated subsidiaries	(4,697)	(5,521)
Loss on extinguishment of debt	412	6,527
Loss (gain) on sale of assets and businesses	(513)	(4,609)
Stock compensation expense	4,927	4,586
Amortization of debt discount, premium and issuance costs	3,136	3,422
Deferred income taxes	78	(3,425)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(45,811)	(118,269)
Other current assets	(8,945)	(7,621)
Other assets	16,633	(48)
Accounts payable	(6,552)	412
Accrued expenses	(11,981)	(18,429)
Income taxes	11,838	15,420
Net cash provided by (used in) operating activities	50,727	(55,861)
Investing activities
Business combinations, net of cash acquired	(515,359)	(9,566)
Purchases of property and equipment	(39,617)	(50,653)
Investment in businesses	(1,754)	(500)
Proceeds from sale of assets and businesses	691	19,512
Net cash provided by (used in) investing activities	(556,039)	(41,207)
Financing activities
Borrowings on revolving facilities	165,000	530,000
Payments on revolving facilities	(150,000)	(415,000)
Proceeds from term loans (financing costs)	779,904	1,139,822
Payments on term loans	(2,875)	(1,170,817)
Revolving facility debt issuance costs	(1,333)	(3,887)
Borrowings of other debt	11,600	6,571
Principal payments on other debt	(5,909)	(5,275)
Dividends paid to Holdings	0	0
Equity investment by Holdings	0	0
Decrease in overdrafts	(7,916)	(17,062)
Proceeds from issuance of non-controlling interests	0	2,094
Distributions to non-controlling interests	(286,641)	(3,657)
Net cash provided by (used in) financing activities	502,446	63,250
Net increase (decrease) in cash and cash equivalents	(2,866)	(33,818)
Cash and cash equivalents at beginning of period	122,549	99,029
Cash and cash equivalents at end of period	119,683	65,211
Consolidating and Eliminating Adjustments
Operating activities
Net income	(38,692)	(33,831)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	0	0
Depreciation and amortization	0	0
Provision for bad debts	0	0
Equity in earnings of unconsolidated subsidiaries	0	0
Equity in earnings of consolidated subsidiaries	38,692	33,831
Loss on extinguishment of debt	0	0
Loss (gain) on sale of assets and businesses	0	0
Stock compensation expense	0	0
Amortization of debt discount, premium and issuance costs	0	0
Deferred income taxes	0	0
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	0	0
Other current assets	0	0
Other assets	0	0
Accounts payable	0	0
Accrued expenses	0	0
Income taxes	0	0
Net cash provided by (used in) operating activities	0	0
Investing activities
Business combinations, net of cash acquired	0	0
Purchases of property and equipment	0	0
Investment in businesses	0	0
Proceeds from sale of assets and businesses	0	0
Net cash provided by (used in) investing activities	0	0
Financing activities
Borrowings on revolving facilities	0	0
Payments on revolving facilities	0	0
Proceeds from term loans (financing costs)	0	0
Payments on term loans	0	0
Revolving facility debt issuance costs	0	0
Borrowings of other debt	0	0
Principal payments on other debt	0	0
Dividends paid to Holdings	0	0
Equity investment by Holdings	0	0
Intercompany	0	0
Decrease in overdrafts	0	0
Proceeds from issuance of non-controlling interests		0
Distributions to non-controlling interests	0	0
Net cash provided by (used in) financing activities	0	0
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Select (Parent Company Only) | Reportable legal entities
Operating activities
Net income	33,739	15,870
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	0	0
Depreciation and amortization	2,207	1,575
Provision for bad debts	0	0
Equity in earnings of unconsolidated subsidiaries	0	0
Equity in earnings of consolidated subsidiaries	(30,425)	(28,256)
Loss on extinguishment of debt	115	6,527
Loss (gain) on sale of assets and businesses	0	0
Stock compensation expense	4,716	4,280
Amortization of debt discount, premium and issuance costs	1,837	2,590
Deferred income taxes	(503)	1,005
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	0	0
Other current assets	(5,890)	(5,761)
Other assets	3,788	(3,753)
Accounts payable	731	2,574
Accrued expenses	(10,370)	(13,406)
Income taxes	6,897	4,256
Net cash provided by (used in) operating activities	6,842	(12,499)
Investing activities
Business combinations, net of cash acquired	0	0
Purchases of property and equipment	(2,269)	(2,937)
Investment in businesses	0	0
Proceeds from sale of assets and businesses	0	0
Net cash provided by (used in) investing activities	(2,269)	(2,937)
Financing activities
Borrowings on revolving facilities	165,000	530,000
Payments on revolving facilities	(150,000)	(415,000)
Proceeds from term loans (financing costs)	(11)	1,139,822
Payments on term loans	(2,875)	(1,147,752)
Revolving facility debt issuance costs	(837)	(3,887)
Borrowings of other debt	5,549	6,571
Principal payments on other debt	(3,226)	(3,704)
Dividends paid to Holdings	(122)	(156)
Equity investment by Holdings	738	617
Intercompany	(10,873)	(85,012)
Decrease in overdrafts	(7,916)	(17,062)
Proceeds from issuance of non-controlling interests		0
Distributions to non-controlling interests	0	0
Net cash provided by (used in) financing activities	(4,573)	4,437
Net increase (decrease) in cash and cash equivalents	0	(10,999)
Cash and cash equivalents at beginning of period	73	11,071
Cash and cash equivalents at end of period	73	72
Subsidiary Guarantors | Reportable legal entities
Operating activities
Net income	25,789	22,737
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	1,334	4,893
Depreciation and amortization	19,409	21,340
Provision for bad debts	42	770
Equity in earnings of unconsolidated subsidiaries	(4,684)	(5,493)
Equity in earnings of consolidated subsidiaries	(8,267)	(5,575)
Loss on extinguishment of debt	0	0
Loss (gain) on sale of assets and businesses	(516)	62
Stock compensation expense	0	0
Amortization of debt discount, premium and issuance costs	0	0
Deferred income taxes	1,383	0
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(28,661)	(83,078)
Other current assets	(572)	(1,126)
Other assets	(562)	(11,531)
Accounts payable	(3,550)	764
Accrued expenses	(2,366)	(5,075)
Income taxes	4,513	0
Net cash provided by (used in) operating activities	3,292	(61,312)
Investing activities
Business combinations, net of cash acquired	(321)	(445)
Purchases of property and equipment	(23,851)	(29,325)
Investment in businesses	(1,749)	(500)
Proceeds from sale of assets and businesses	691	7
Net cash provided by (used in) investing activities	(25,230)	(30,263)
Financing activities
Borrowings on revolving facilities	0	0
Payments on revolving facilities	0	0
Proceeds from term loans (financing costs)	0	0
Payments on term loans	0	0
Revolving facility debt issuance costs	0	0
Borrowings of other debt	0	0
Principal payments on other debt	(145)	(80)
Dividends paid to Holdings	0	0
Equity investment by Holdings	0	0
Intercompany	22,729	92,074
Decrease in overdrafts	0	0
Proceeds from issuance of non-controlling interests		0
Distributions to non-controlling interests	0	(50)
Net cash provided by (used in) financing activities	22,584	91,944
Net increase (decrease) in cash and cash equivalents	646	369
Cash and cash equivalents at beginning of period	4,856	6,467
Cash and cash equivalents at end of period	5,502	6,836
Non-Guarantor Subsidiaries | Reportable legal entities
Operating activities
Net income	13,488	6,859
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	30	18
Depreciation and amortization	4,008	3,501
Provision for bad debts	0	0
Equity in earnings of unconsolidated subsidiaries	(13)	(28)
Equity in earnings of consolidated subsidiaries	0	0
Loss on extinguishment of debt	0	0
Loss (gain) on sale of assets and businesses	0	(4,671)
Stock compensation expense	0	0
Amortization of debt discount, premium and issuance costs	0	0
Deferred income taxes	(5)	0
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(13,414)	(23,563)
Other current assets	1,304	(1,514)
Other assets	599	15,072
Accounts payable	(870)	(5,480)
Accrued expenses	434	5,342
Income taxes	(111)	0
Net cash provided by (used in) operating activities	5,450	(4,464)
Investing activities
Business combinations, net of cash acquired	(22)	0
Purchases of property and equipment	(6,876)	(9,705)
Investment in businesses	0	0
Proceeds from sale of assets and businesses	0	19,505
Net cash provided by (used in) investing activities	(6,898)	9,800
Financing activities
Borrowings on revolving facilities	0	0
Payments on revolving facilities	0	0
Proceeds from term loans (financing costs)	0	0
Payments on term loans	0	0
Revolving facility debt issuance costs	0	0
Borrowings of other debt	5,326	0
Principal payments on other debt	(957)	(695)
Dividends paid to Holdings	0	0
Equity investment by Holdings	0	0
Intercompany	(2,467)	(7,062)
Decrease in overdrafts	0	0
Proceeds from issuance of non-controlling interests		2,094
Distributions to non-controlling interests	(1,266)	(1,324)
Net cash provided by (used in) financing activities	636	(6,987)
Net increase (decrease) in cash and cash equivalents	(812)	(1,651)
Cash and cash equivalents at beginning of period	4,561	5,056
Cash and cash equivalents at end of period	3,749	3,405
Non-Guarantor Concentra | Reportable legal entities
Operating activities
Net income	9,658	11,828
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	0	0
Depreciation and amortization	21,147	16,123
Provision for bad debts	43	11
Equity in earnings of unconsolidated subsidiaries	0	0
Equity in earnings of consolidated subsidiaries	0	0
Loss on extinguishment of debt	297	0
Loss (gain) on sale of assets and businesses	3	0
Stock compensation expense	211	306
Amortization of debt discount, premium and issuance costs	1,299	832
Deferred income taxes	(797)	(4,430)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(3,736)	(11,628)
Other current assets	(3,787)	780
Other assets	12,808	164
Accounts payable	(2,863)	2,554
Accrued expenses	321	(5,290)
Income taxes	539	11,164
Net cash provided by (used in) operating activities	35,143	22,414
Investing activities
Business combinations, net of cash acquired	(515,016)	(9,121)
Purchases of property and equipment	(6,621)	(8,686)
Investment in businesses	(5)	0
Proceeds from sale of assets and businesses	0	0
Net cash provided by (used in) investing activities	(521,642)	(17,807)
Financing activities
Borrowings on revolving facilities	0	0
Payments on revolving facilities	0	0
Proceeds from term loans (financing costs)	779,915	0
Payments on term loans	0	(23,065)
Revolving facility debt issuance costs	(496)	0
Borrowings of other debt	725	0
Principal payments on other debt	(1,581)	(796)
Dividends paid to Holdings	0	0
Equity investment by Holdings	0	0
Intercompany	(9,389)	0
Decrease in overdrafts	0	0
Proceeds from issuance of non-controlling interests		0
Distributions to non-controlling interests	(285,375)	(2,283)
Net cash provided by (used in) financing activities	483,799	(26,144)
Net increase (decrease) in cash and cash equivalents	(2,700)	(21,537)
Cash and cash equivalents at beginning of period	113,059	76,435
Cash and cash equivalents at end of period	110,359	54,898
Select Medical Corporation
Operating activities
Net income	43,982	23,463
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Distributions from unconsolidated subsidiaries	1,364	4,911
Depreciation and amortization	46,771	42,539
Provision for bad debts	85	781
Equity in earnings of unconsolidated subsidiaries	(4,697)	(5,521)
Equity in earnings of consolidated subsidiaries	0	0
Loss on extinguishment of debt	412	6,527
Loss (gain) on sale of assets and businesses	(513)	(4,609)
Stock compensation expense	4,927	4,586
Amortization of debt discount, premium and issuance costs	3,136	3,422
Deferred income taxes	78	(3,425)
Changes in operating assets and liabilities, net of effects of business combinations:
Accounts receivable	(45,811)	(118,269)
Other current assets	(8,945)	(7,621)
Other assets	16,633	(48)
Accounts payable	(6,552)	412
Accrued expenses	(11,981)	(18,429)
Income taxes	11,838	15,420
Net cash provided by (used in) operating activities	50,727	(55,861)
Investing activities
Business combinations, net of cash acquired	(515,359)	(9,566)
Purchases of property and equipment	(39,617)	(50,653)
Investment in businesses	(1,754)	(500)
Proceeds from sale of assets and businesses	691	19,512
Net cash provided by (used in) investing activities	(556,039)	(41,207)
Financing activities
Borrowings on revolving facilities	165,000	530,000
Payments on revolving facilities	(150,000)	(415,000)
Proceeds from term loans (financing costs)	779,904	1,139,822
Payments on term loans	(2,875)	(1,170,817)
Revolving facility debt issuance costs	(1,333)	(3,887)
Borrowings of other debt	11,600	6,571
Principal payments on other debt	(5,909)	(5,275)
Dividends paid to Holdings	(122)	(156)
Equity investment by Holdings	738	617
Intercompany	0	0
Decrease in overdrafts	(7,916)	(17,062)
Proceeds from issuance of non-controlling interests	0	2,094
Distributions to non-controlling interests	(286,641)	(3,657)
Net cash provided by (used in) financing activities	502,446	63,250
Net increase (decrease) in cash and cash equivalents	(2,866)	(33,818)
Cash and cash equivalents at beginning of period	122,549	99,029
Cash and cash equivalents at end of period	$ 119,683	$ 65,211